Takara Bio

Shiga, Japan (Kusatsu, Shiga Prefecture)
CAR-T Lentiviral
8 confirmed programs · 4 sponsors · Last scored 2026-04-29
58.8
Signal Score
○ FDA Inspections ✓ Clinical Trials (8) ○ SEC Filings ✓ Press (16) ○ EMA GMP ○ MHRA GMP

Quick Facts: Takara Bio

Signal Score
58.8/100 (as of 2026-04-29)
Quality Compliance
Assessment pending
Headquarters
Shiga, Japan (Kusatsu, Shiga Prefecture)
Modalities
CAR-T, Lentiviral
Active Programs
8 confirmed from ClinicalTrials.gov across 4 sponsors
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About Takara Bio

Pure-play CDMO.

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations 56.2
8 active programs across 4 sponsors
Modalities: CAR-T, Lentiviral
5 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov
8 active programs across 4 sponsors · Modalities: CAR-T, Lentiviral · 5 programs in advanced phases (Phase 2/3)
Programs 8
Sponsors4
ModalitiesCAR-T, Lentiviral
8 active programs across 4 sponsors
Modalities: CAR-T, Lentiviral
5 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov facility matching
NCT07174427 Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel;... PHASE3 Recruiting
NCT05963217 Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen... PHASE1 Recruiting
NCT03250325 Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced... PHASE1/PHASE2 Completed
NCT03155191 Study of TBI-1501 for Relapsed or Refractory Acute... PHASE1/PHASE2 Active Not Recruiting
NCT02418598 AADC Gene Therapy for Parkinson's Disease PHASE1/PHASE2 Terminated
NCT02366546 Investigator Initiated Phase 1 Study of TBI-1301 PHASE1 Unknown
NCT02134262 Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR... PHASE1/PHASE2 Unknown
NCT02096614 Investigator Initiated Phase 1 Study of TBI-1201 PHASE1 Completed
Source: ClinicalTrials.gov · Retrieved Jul 04, 2026
Financial Stability 60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity 61.0
Regulatory milestones (2 articles)
Sites: Shiga, JP
Source: SEC EDGAR, press monitoring, company profiles
1 manufacturing site
Recent Press16 articles
Regulatory milestones (2 articles)

Recent News 16 articles

general 2026-05-04
AI in Plasmid DNA Manufacturing Market Is Going to Boom| Roche, Takara Bio, Agilent Technologies - openPR.com
AI in Plasmid DNA Manufacturing Market Is Going to Boom| Roche, Takara Bio, Agilent Technologies  openPR.com
Source →
regulatory 2026-04-24
Takara Bio, Resistomap join forces to streamline AMR surveillance from environmental samples - Indian Pharma Post
Takara Bio, Resistomap join forces to streamline AMR surveillance from environmental samples  Indian Pharma Post
Source →
general 2026-04-20
Takara Bio USA, Inc. Validates New Class of Spatial Technology with Benchmark Study for Cancer Research - BioSpace
Takara Bio USA, Inc. Validates New Class of Spatial Technology with Benchmark Study for Cancer Research  BioSpace
Source →
general 2026-04-19
Takara Bio Inc stock (JP3463000004): Is its biotech tools leadership strong enough for steady growth - AD HOC NEWS
Takara Bio Inc stock (JP3463000004): Is its biotech tools leadership strong enough for steady growth  AD HOC NEWS
Source →
general 2026-04-19
Takara Bio Inc stock (JP3463000004): Is its biotech tools leadership strong enough for steady growth - AD HOC NEWS
Takara Bio Inc stock (JP3463000004): Is its biotech tools leadership strong enough for steady growth  AD HOC NEWS
Source →
regulatory 2026-04-19
Takara Bio and Resistomap forge deal to speed up global fight against superbugs - Indian Pharma Post
Takara Bio and Resistomap forge deal to speed up global fight against superbugs  Indian Pharma Post
Source →
general 2026-04-17
Takara Bio USA, Inc. Launches Certified Service Provider Program to Advance Research Using NGS and Single-Cell Technologies - BioSpace
Takara Bio USA, Inc. Launches Certified Service Provider Program to Advance Research Using NGS and Single-Cell Technologies  BioSpace
Source →
general 2026-04-16
Takara Bio USA, Inc. Launches Certified Service Provider Program to Advance Research Using NGS and S - PharmiWeb.com
Takara Bio USA, Inc. Launches Certified Service Provider Program to Advance Research Using NGS and S  PharmiWeb.com
Source →
general 2026-04-15
Takara Bio Inc stock (JP3463000004): Is biotech gene editing strength enough to drive U.S. investor - AD HOC NEWS
Takara Bio Inc stock (JP3463000004): Is biotech gene editing strength enough to drive U.S. investor  AD HOC NEWS
Source →
general 2026-04-14
Takara Bio Inc stock (JP3463000004): Is biotech innovation strong enough to drive global upside? - AD HOC NEWS
Takara Bio Inc stock (JP3463000004): Is biotech innovation strong enough to drive global upside?  AD HOC NEWS
Source →
general 2026-04-14
Takara Bio Inc stock (JP3463000004): Is biotech innovation strong enough to drive global upside? - AD HOC NEWS
Takara Bio Inc stock (JP3463000004): Is biotech innovation strong enough to drive global upside?  AD HOC NEWS
Source →
general 2026-03-31
Takara Bio USA and Hamilton Company Partner to Automate NGS Library Preparation - BioSpace
Takara Bio USA and Hamilton Company Partner to Automate NGS Library Preparation  BioSpace
Source →
general 2026-03-30
Takara Bio USA and Hamilton Partner for Automated NGS Library Prep - San Jose Today - National Today
Takara Bio USA and Hamilton Partner for Automated NGS Library Prep  National Today
Source →
general 2026-03-30
Takara Bio USA and Hamilton Company Partner to Automate NGS Library Preparation - Business Wire
Takara Bio USA and Hamilton Company Partner to Automate NGS Library Preparation  Business Wire
Source →
general 2026-03-27
TAKARA BIO PB Ratio: 1.36 — 56% Below Median - gurufocus.com
TAKARA BIO PB Ratio: 1.36 — 56% Below Median  gurufocus.com
Source →
partnership 2026-02-26
Takara Bio USA, Inc. Collaborates with Illumina on Spatial Transcriptomics Workflow, Details Presented at AGBT 2026 - BioSpace
Takara Bio USA, Inc. Collaborates with Illumina on Spatial Transcriptomics Workflow, Details Presented at AGBT 2026  BioSpace
Source →

Frequently Asked Questions About Takara Bio

How many clinical programs is Takara Bio linked to?
Takara Bio is associated with 8 clinical trials in CDMO Signal's ClinicalTrials.gov-sourced data.
What is Takara Bio's CDMO Signal Score?
Takara Bio has a Signal Score of 59/100, based on quality, operations, financial stability, and capacity data.
Evaluating Takara Bio for a manufacturing program?
Use the free AI matchmaker to compare Takara Bio against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
CAR-T CDMOs → Lentiviral CDMOs →

Similar CDMOs

Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 91.7
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Signal Score: 80.6
CAR-T, Cell Therapy, AAV, Lentiviral, ADC, Monoclonal Antibody, Recombinant Protein
OmniaBio
Hamilton, ON
Signal Score: 79.5
AAV, Lentiviral, CAR-T, Cell Therapy
ElevateBio BaseCamp
Waltham, MA
Signal Score: 59.0
AAV, Lentiviral, CAR-T
Rose BioSolutions
Rockville, MD
Plasmid DNA, AAV, Lentiviral, Adenoviral, CAR-T, Cell Therapy, Gene Editing, Cell Solutions / Starting Materials